Literature DB >> 11086072

Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.

Y T Tai1, G Teoh, B Lin, F E Davies, D Chauhan, S P Treon, N Raje, T Hideshima, Y Shima, K Podar, K C Anderson.   

Abstract

Ku is a heterodimer of Ku70 and Ku86 that binds to double-stranded DNA breaks (DSBs), activates the catalytic subunit (DNA-PKcs) when DNA is bound, and is essential in DSB repair and V(D)J recombination. Given that abnormalities in Ig gene rearrangement and DNA damage repair are hallmarks of multiple myeloma (MM) cells, we have characterized Ku expression and function in human MM cells. Tumor cells (CD38(+)CD45RA(-)) from 12 of 14 (86%) patients preferentially express a 69-kDa variant of Ku86 (Ku86v). Immunoblotting of whole cell extracts (WCE) from MM patients shows reactivity with Abs targeting Ku86 N terminus (S10B1) but no reactivity with Abs targeting Ku86 C terminus (111), suggesting that Ku86v has a truncated C terminus. EMSA confirmed a truncated C terminus in Ku86v and further demonstrated that Ku86v in MM cells had decreased Ku-DNA end binding activity. Ku86 forms complexes with DNA-PKcs and activates kinase activity, but Ku86v neither binds DNA-PKcs nor activates kinase activity. Furthermore, MM cells with Ku86v have increased sensitivity to irradiation, mitomycin C, and bleomycin compared with patient MM cells or normal bone marrow donor cells with Ku86. Therefore, this study suggests that Ku86v in MM cells may account for decreased DNA repair and increased sensitivity to radiation and chemotherapeutic agents, whereas Ku86 in MM cells confers resistance to DNA damaging agents. Coupled with a recent report that Ku86 activity correlates with resistance to radiation and chemotherapy, these results have implications for the potential role of Ku86 as a novel therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086072     DOI: 10.4049/jimmunol.165.11.6347

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

Review 2.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

Review 3.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

4.  Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Authors:  Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

5.  Impaired NHEJ function in multiple myeloma.

Authors:  Clara Yang; Christopher Betti; Sheetal Singh; Amir Toor; Andrew Vaughan
Journal:  Mutat Res       Date:  2008-11-05       Impact factor: 2.433

6.  Lack of Ku80 alteration in multiple myeloma.

Authors:  Miyuki Kato; Shinsuke Iida; Hirokazu Komatsu; Ryuzo Ueda
Journal:  Jpn J Cancer Res       Date:  2002-04

7.  Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification.

Authors:  Michael J Difilippantonio; Simone Petersen; Hua Tang Chen; Roger Johnson; Maria Jasin; Roland Kanaar; Thomas Ried; André Nussenzweig
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

8.  Ku86 exists as both a full-length and a protease-sensitive natural variant in multiple myeloma cells.

Authors:  Charles A Gullo; Feng Ge; Geraline Cow; Gerrard Teoh
Journal:  Cancer Cell Int       Date:  2008-04-29       Impact factor: 5.722

9.  A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Authors:  Lijie Xing; Liang Lin; Tengteng Yu; Yuyin Li; Shih-Feng Cho; Jiye Liu; Kenneth Wen; Phillip A Hsieh; Krista Kinneer; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-02-14       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.